Blood biomarkers like p-tau217 are emerging as a way to detect Alzheimer's disease. The first FDA-approved blood-based ...

Today's systematic and more subtle random defects are not only decreasing yields, but are also increasing the number of test escapes, or defective parts per million (DPPM) shipped out. One of the ...

A finger-prick blood test that can be mailed to a lab may offer a simpler way to detect the brain changes linked to Alzheimer ...

A new international study has demonstrated that Alzheimer's disease biomarkers can be accurately detected using simple finger ...

Once integration is completed, the partners plan to accelerate commercial rollout across India, anticipated in 2026.

A Fort Lauderdale-based manufacturer of blood glucose testing products knowingly distributed defective test strips that delivered inaccurate results and created health problems for patients with ...

Alzheimer’s disease blood test developer Quanterix put forward new clinical data from its Simoa assay, which it described as ...

Charlotte, N.C. — The IC design community has begun to question its goal of achieving fewer than 100 defective parts per million. Citing the difficulty and costs associated with the stringent ...

From robotic surgery performed 7,000 miles away to the first blood test to help diagnose Alzheimer’s disease, 2025 has been a ...

As the semiconductor world excitingly explores the potential of new advanced package solutions for their intricate and novel designs, challenges arise from undetected defects caused by the complexity ...